BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190130
DTEND;VALUE=DATE:20190201
DTSTAMP:20260514T232813
CREATED:20181031T153442Z
LAST-MODIFIED:20181031T154321Z
UID:18198-1548806400-1548979199@www.pharmajournalist.com
SUMMARY:3rd Annual CAR-T Congress EU
DESCRIPTION:CAR-T cell therapy has shown unparalleled success in haematological malignancies\, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA\, and following recent approval by the EMA\, it is a landmark time for the industry. \n \nDespite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field\, to maximise the potential of this ground-breaking therapy. \nHear first-hand the story behind the successes of Novartis & Kite on their roads to approval. Discover how to improve manufacturing with automation to lower cost and increase the scope and reach of the therapies from innovators such as Torque Therapeutics. Explore the viability of allogeneic CAR-T with Cellectis\, Celyad and Servier on their approaches to off-the-shelf products. Atillio Bondanza also shares strategies to improve safety with a better understanding of the underlying mechanisms of toxicity. \n20+ industry leaders will be offering insight on: \n\nSolid tumour targeting: overcoming the tumour microenvironment\nMulti-specific & dual targeting CARs\nProcess development\, scalability & automation\nAllogeneic vs Autologous: the potential of off-the-shelf therapies\nPatient access\, implementation & regulatory challenges\nAdvances in gene engineering\nSafety and toxicity\n\nThere is also a dedicated poster session\, whereby attendees can showcase their latest research to the CAR-T community\, deadline for submissions 14th December 2018. \nSave up to £300 by booking on the early bird rate before Friday 30th November 2018. 2019 is going to be a big year for CAR-T in Europe\, don’t be the one to miss out on the latest developments. \nTo learn more about this event\, and to register online\, visit www.car-tcongresseu.com
URL:https://www.pharmajournalist.com/event/3rd-annual-car-t-congress-eu/
LOCATION:Millennium Gloucester Hotel\, 4-18 Harrington Gardens\, Kensington\, London\, SW7 4LH\, United Kingdom
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR